Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary
2008

Effects of Adding a Second Diabetes Drug After Metformin Fails

Sample size: 414 publication Evidence: moderate

Author Information

Author(s): Jermendy György, Erdesz Diana, Nagy Laszlo, Yin Don, Phatak Hemant, Karve Sudeep, Engel Samuel, Balkrishnan Rajesh

Primary Institution: Bajcsy-Zsilinszly Hospital

Hypothesis

What is the status of glycemic control and patient-reported outcomes in Hungarian patients with type 2 diabetes who were prescribed additional medications after metformin monotherapy failure?

Conclusion

Nearly 75% of patients were not at A1C goal of < 6.5% despite using two oral anti-hyperglycemic medications.

Supporting Evidence

  • Approximately 75% of patients were not at glycemic goal after the addition of sulfonylurea or thiazolidinedione to their metformin monotherapy.
  • Patients not at glycemic goal reported being less likely to take medications exactly as prescribed.
  • Self-reported hypoglycemia was negatively associated with health-related quality of life.

Takeaway

Most people with diabetes in this study didn't get their blood sugar under control even after taking extra medicine. Some even had low blood sugar that made them feel sick.

Methodology

This observational study assessed glycemic control and patient-reported outcomes in type 2 diabetes patients who added a sulfonylurea or thiazolidinedione to metformin therapy.

Potential Biases

Potential bias due to self-reported data and observational design.

Limitations

The study was observational and cannot infer causality; detailed reasons for medication changes were not collected.

Participant Demographics

Mean age of participants was 60.5 years, with 49.8% female.

Statistical Information

P-Value

0.017

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1477-7525-6-88

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication